Description: In this webinar, Drs. Nathanson and Shah will describe the biological basis for pathogenicity of variants and the clinical interpretation of genetic testing results. Additionally the speakers will provide insight into the clinical significance of pathogenic variants with a focus on BRCA1 and BRCA2, including risk mitigation measures and therapeutic implications.
Duration: 1 hr
Level of Instruction: Basic
AMA PRA Category 1 Credit(s) &trade
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Association for Molecular Pathology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CMLE Credit: The ASCP designates this activity for a maximum of 1.0 Continuing Medical Laboratory Education (CMLE) credit hour. CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
SAM Credit: This activity is approved by the American Board of Pathology for up to 1.00 SAM credit. Physicians should claim only credit commensurate with the extent of their participation in the activity. Learners must pass the post-test with a score of 80% or higher and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for an accrediting board other than the ABP, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
“Targeting DNA Repair Pathways: Current and Future Implications of PARP Inhibitors” is an up-to-date and useful three-part webcast series that will cover: 1. The mechanism of action of PARP inhibitors and the science of Homologous Recombination Deficiency (HRD) testing, 2. Laboratory considerations (from sample acquisition to result reporting) for HRD testing, and 3. Clinical considerations for testing and treatment and the need for genetic counseling.
This program has been supported through educational grants from AstraZeneca & Merck
Discuss the interpretation of variants in BRCA1/2, touching on genotype/phenotype correlation
Describe the three major categories of genetic testing results (benign, variant of uncertain significance, pathogenic/likely pathogenic)
Explain the main cancer prevention measures suggested for individuals with germline BRCA1 and BRCA2 mutations
Describe the current role of PARP inhibitors in the clinic
Live Webinar Information
October 22, 2019 1:00 PM Eastern
12:00 PM Central, 11:00 AM Mountain, 10:00 AM Pacific
Add to Calendar:
Registration Time Remaining:
34 days, 19 hours
AMP Regular Member Price:
AMP Technologist Member Price:
AMP Associate Member Price:
Cookies are small pieces of information that are stored by your browser on your computerâ€™s hard drive.
You can delete or block cookies within your browser settings.
Should you opt to do this, some parts of our site may not work.
For more information, including instructions on how to remove the cookies that have been placed,